Concert Pharmaceuticals to Present at the Thomas Weisel Partners 2009 Healthcare Conference on September 10, 2009
LEXINGTON, Mass -- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the Thomas Weisel Partners 2009 Healthcare Conference on Thursday, September 10, 2009 at 10:55 a.m. Eastern Time. The conference will be held September 9-11, 2009 at the Four Seasons Hotel in Boston, Massachusetts.
Concert Pharmaceuticals is a clinical stage biotechnology company focused on the application of deuterium chemistry to create novel small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others. Its lead development candidate is the HIV protease inhibitor CTP-518. In 2009, Concert entered into a potential $1 billion collaboration with GlaxoSmithKline to develop certain deuterium-containing medicines. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.
CoNCERT and CoNCERT Pharmaceuticals are trademarks of Concert Pharmaceuticals, Inc.